Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$18.42M+334.57%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Aballi
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 216
- Beta
- 2.24
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.74
Financials
Revenue
$18.42M+334.6%Net Income
$-6.34MEBITDA
$-5.14MFree Cash Flow
$-2.77MEPS (diluted)
$-0.25Shares Outstanding (diluted)
24.85M+39757.9%Operating Expenses
$15.24MCash & Debt
$28.09MReturn of Capital
$0.00Revenue by Segment (annual)
$66.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $66.58M | $-19.95M | $-0.93 |
| 2024 | $55.64M | $-15.12M | $-0.83 |
| 2023 | $52.55M | $-23.69M | $-1.34 |
| 2022 | $45.56M | $-47.39M | $-2.77 |
| 2021 | $48.30M | $-26.85M | $-1.68 |
| 2020 | $41.98M | $-16.69M | $-1.32 |
| 2019 | $40.39M | $-12.04M | $-0.96 |
| 2018 | $32.44M | $-8.01M | $-127.16 |
| 2017 | $26.81M | $-25.63M | $-406.81 |
| 2015 | $17.95M | $-19.18M | $-305.48 |
| 2014 | $11.66M | $-14.98M | $-265.79 |
| 2013 | $3.06M | $-13.50M | $-251.43 |
| 2012 | $926.0K | $-7.32M | $-206.86 |
Valuation
XGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
24-52.00%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·9d ago·Negative
…ing Downgrade) Exagen is downgraded to Hold as Q3 results reveal slower revenue growth, weaker margins, and higher operating losses, clouding the turnaround outlook. XGN's Q3 revenue grew 7% year-over-year but declined 8% sequentially, with gross margin slipping to 58.8% and operating expenses rising 16%. Growth initiatives like myositis launch, Pharma Services, and an AI software offer optionality but require execution and time to impact profitability.
View source ↗ - Newsmarketbeat.com·12d ago·Positive
What Exagen (XGN) Said on Its Q3 Earnings Call Exagen NASDAQ: XGN reported third-quarter revenue of $18.4 million, up 7% from a year earlier, as higher test volume and pricing helped the autoimmune diagnostics company post what management described as its strongest third quarter on record.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·12d ago·Negative
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
View source ↗ - Newsglobenewswire.com·12d ago·Negative
Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a precision medicine company bringing clarity to autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and recent corporate updates.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Exagen Inc. to Participate in Upcoming Investor Conferences Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Exagen to Announce Third Quarter Financial Results on November 10, 2026 CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the market opens on Tuesday, November 10, 2026.
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $-0.19 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.25 vs $-0.18miss
- Tue, Aug 4$-0.13 vs $-0.19beat
- Mon, May 11$-0.17 vs $-0.24beat
- Tue, Mar 10$-0.20 vs $-0.20beat
- Tue, Nov 4$-0.31 vs $-0.16miss
- Tue, Jul 29$-0.18 vs $-0.18beat
Estimates and results for XGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XGN officers and directors.
- Bought
- $1.0m
- Sold
- $3.9m
9 trades
20 trades
- Chernett Joreysold
- Chernett Joreysold
- Chernett Joreybought
- Chernett Joreybought
- Chernett Joreybought
- Chernett Joreysold
- Chernett Joreybought
- Aballi Johnsold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
